Jörg Neermann, PhD, advises various biotech companies and a venture capital fund (Vorwerk Ventures) and serves on the boards of directors of several biotech and healthcare companies. He is the former CEO of the privately held German biotech company Curexsys GmbH, which he built from start-up to clinical readiness. Prior to this, he worked for more than fourteen years as a Partner at a leading European life science-focused investment firm LSP. Prior to joining LSP, Jörg was Managing Director at DVC Deutsche Venture Capital, a venture capital and private equity division of Deutsche Bank, where he built and ran its healthcare investment franchise. Previously, he started his venture capital career with Atlas Venture as an associate and investment manager.

During his career, he led and completed more than 80 financing transactions and was intimately involved in more than 15 M&A transactions and IPOs with a total transaction volume exceeding a billion euros. Dr. Neermann has a strong scientific background and hands-on finance and investment expertise and has served on the boards of numerous private and public European biotech and life science companies. He is currently a non-executive director at Nasdaq-listed Immunic Inc. (IMUX) and at the German healthcare companies numares AG, Smart Reporting GmbH and Hema.to GmbH. 

Jörg studied biotechnology at the Technical University of Braunschweig, Germany, and the Massachusetts Institute of Technology in Cambridge, MA, and holds a master’s degree and a PhD in biotechnology from the Technical University of Braunschweig, Germany. He also studied economics at the Technical University of Braunschweig, Germany, and at Harvard Business School.